Literature DB >> 12366715

Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution?

Franca Radaelli1, Rita Mazza, Elisabetta Curioni, Alberto Ciani, Mauro Pomati, Anna-Teresa Maiolo.   

Abstract

Essential thrombocythemia (ET) is a chronic myeloproliferative disorder that can rarely undergo leukemic transformation either in treated (3-7%) or untreated patients (1%). Evolution to myeloblastic or myelomonoblastic acute leukemia is commonly described in the literature, whereas lymphatic and megakaryocytic forms are considered unusual. Here, we report three cases of acute megakaryocytic leukemia (LMA-M7) among 11 acute leukemic transformations observed in our series of 321 ET patients. LMA-M7 was diagnosed employing immunophenotyping according to FAB criteria. These recurrences of LMA M7 suggest that this kind of evolution cannot be considered rare or casual in ET.

Entities:  

Mesh:

Year:  2002        PMID: 12366715     DOI: 10.1034/j.1600-0609.2002.02734.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

1.  JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Authors:  Thomas Mercher; Gerlinde Wernig; Sandra A Moore; Ross L Levine; Ting-Lei Gu; Stefan Fröhling; Dana Cullen; Roberto D Polakiewicz; Olivier A Bernard; Titus J Boggon; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

Review 2.  Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.

Authors:  Shinsuke Mizutani; Junya Kuroda; Daisuke Shimizu; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2010-02-11       Impact factor: 2.490

3.  Clinical diagnosis of adult patients with acute megakaryocytic leukemia.

Authors:  Guangjie Zhao; Wanling Wu; Xiaoqin Wang; Jingwen Gu
Journal:  Oncol Lett       Date:  2018-09-25       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.